Jennifer Lachey - Nov 10, 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Nov 10, 2021
Transactions value $
-$1,263,698
Form type
4
Date filed
11/12/2021, 03:40 PM
Previous filing
Nov 5, 2021
Next filing
Dec 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $4.77K +15.9K +18.55% $0.30* 102K Nov 10, 2021 Direct
transaction KROS Common Stock Sale -$954K -15.9K -15.65% $60.00 85.7K Nov 10, 2021 Direct F1
transaction KROS Common Stock Options Exercise $1.59K +5.3K +6.18% $0.30* 91K Nov 11, 2021 Direct
transaction KROS Common Stock Sale -$43.4K -739 -0.81% $58.73 90.3K Nov 11, 2021 Direct F1, F2
transaction KROS Common Stock Sale -$273K -4.56K -5.05% $59.78 85.7K Nov 11, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -15.9K -13.35% $0.00 103K Nov 10, 2021 Common Stock 15.9K $0.30 Direct F4
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -5.3K -5.14% $0.00 97.9K Nov 11, 2021 Common Stock 5.3K $0.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.125 to $59.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.145 to $60.07 inclusive.
F4 Immediately exercisable.